Insider Stock Trading History of Kakkis Emil D


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Kakkis Emil D since year 2005. The trader's CIK number is 1248093. At the time of this reporting, Kakkis Emil D is the President & CEO of Ultragenyx Pharmaceutical Inc. . (stock ticker symbol RARE). See this page for all insider trading activities at Ultragenyx Pharmaceutical Inc. .

Note that in the past KAKKIS EMIL D also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Kakkis Emil D since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-08-28 RARE Ultragenyx Pharmaceutical Inc. Buy 7,500 52.68 395,100
2016-11-15 RARE Ultragenyx Pharmaceutical Inc. Sale 20,000 81.39 1,627,800
2016-10-14 RARE Ultragenyx Pharmaceutical Inc. Sale 20,000 63.55 1,271,100
2016-08-15 RARE Ultragenyx Pharmaceutical Inc. Sale 20,000 67.75 1,355,100
2016-07-15 RARE Ultragenyx Pharmaceutical Inc. Sale 20,000 50.98 1,019,500
2016-05-16 RARE Ultragenyx Pharmaceutical Inc. Sale 20,000 60.74 1,214,800
2016-04-15 RARE Ultragenyx Pharmaceutical Inc. Sale 20,000 70.29 1,405,800
2015-12-30 RARE Ultragenyx Pharmaceutical Inc. Sale 14,502 114.94 1,666,932
2015-12-31 RARE Ultragenyx Pharmaceutical Inc. Sale 5,498 113.78 625,578
2015-11-30 RARE Ultragenyx Pharmaceutical Inc. Sale 20,000 98.09 1,961,900
2015-10-30 RARE Ultragenyx Pharmaceutical Inc. Sale 20,000 99.92 1,998,400
2009-03-02 BMRN Biomarin Pharmaceutical Inc Option Ex 7,897 6.43 50,777
2009-03-02 BMRN Biomarin Pharmaceutical Inc Sale 7,897 11.70 92,394
2009-02-03 BMRN Biomarin Pharmaceutical Inc Sale 17,000 19.14 325,363
2009-02-03 BMRN Biomarin Pharmaceutical Inc Option Ex 17,000 6.43 109,310
2009-01-02 BMRN Biomarin Pharmaceutical Inc Sale 17,000 17.57 298,690
2009-01-02 BMRN Biomarin Pharmaceutical Inc Option Ex 17,000 6.28 106,760
2008-12-01 BMRN Biomarin Pharmaceutical Inc Option Ex 17,000 6.13 104,210
2008-12-01 BMRN Biomarin Pharmaceutical Inc Sale 17,000 15.87 269,790
2008-11-25 BMRN Biomarin Pharmaceutical Inc Sale 75,000 15.98 1,198,725
2008-10-31 BMRN Biomarin Pharmaceutical Inc Buy 317 13.35 4,233
2008-11-03 BMRN Biomarin Pharmaceutical Inc Option Ex 33,000 12.12 400,026
2008-10-01 BMRN Biomarin Pharmaceutical Inc Option Ex 18,000 6.13 110,340
2008-10-01 BMRN Biomarin Pharmaceutical Inc Sale 18,000 26.27 472,878
2008-09-02 BMRN Biomarin Pharmaceutical Inc Sale 18,000 30.19 543,384
2008-09-02 BMRN Biomarin Pharmaceutical Inc Option Ex 6,000 6.13 36,780
2008-08-01 BMRN Biomarin Pharmaceutical Inc Sale 18,000 32.46 584,352
2008-07-07 BMRN Biomarin Pharmaceutical Inc Sale 18,000 28.04 504,792
2008-06-02 BMRN Biomarin Pharmaceutical Inc Option Ex 16,000 4.00 64,000
2008-06-02 BMRN Biomarin Pharmaceutical Inc Sale 18,000 37.63 677,286
2008-05-01 BMRN Biomarin Pharmaceutical Inc Sale 18,000 37.46 674,262
2008-05-01 BMRN Biomarin Pharmaceutical Inc Option Ex 18,000 4.00 72,000
2008-04-30 BMRN Biomarin Pharmaceutical Inc Buy 1,640 10.37 17,006
2008-04-29 BMRN Biomarin Pharmaceutical Inc Option Ex 75,000 4.00 300,000
2008-04-01 BMRN Biomarin Pharmaceutical Inc Sale 9,857 35.92 354,102
2008-04-01 BMRN Biomarin Pharmaceutical Inc Option Ex 18,000 4.00 72,000
2008-04-01 BMRN Biomarin Pharmaceutical Inc Sale 8,143 35.75 291,087
2008-03-06 BMRN Biomarin Pharmaceutical Inc Sale 18,000 38.15 686,610
2008-03-06 BMRN Biomarin Pharmaceutical Inc Option Ex 18,000 4.00 72,000
2007-10-31 BMRN Biomarin Pharmaceutical Inc Buy 2,038 6.92 14,100
2007-04-30 BMRN Biomarin Pharmaceutical Inc Buy 2,982 5.18 15,461
2006-01-04 BMRN Biomarin Pharmaceutical Inc Option Ex 50,000 4.00 200,000
2006-10-31 BMRN Biomarin Pharmaceutical Inc Buy 4,368 3.43 14,999

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kakkis Emil D (President & CEO of Ultragenyx Pharmaceutical Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.